LXRX
Lexicon Pharmaceuticals, Inc.NASDAQHealthcare$1.59-3.05%ClosedMarket Cap: $673.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.37
P/S
13.53
EV/EBITDA
-16.44
DCF Value
$-10.82
FCF Yield
-10.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.9%
Operating Margin
-98.2%
Net Margin
-101.1%
ROE
-41.9%
ROA
-27.2%
ROIC
-28.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $5.5M | 94.2% | $-14.8M | $-15.5M | $-0.04 | — |
| FY 2025 | $49.8M | 99.4% | $-48.9M | $-50.3M | $-0.14 | — |
| Q3 2025 | $14.2M | 99.9% | $-12.2M | $-12.8M | $-0.04 | — |
| Q2 2025 | $28.9M | 99.3% | $3.7M | $3.3M | $0.01 | — |
| Q1 2025 | $1.3M | 97.6% | $-25.7M | $-25.3M | $-0.07 | — |
| Q4 2024 | $26.6M | 2.3% | $-32.7M | $-33.8M | $-0.09 | — |
| FY 2024 | $31.1M | 98.0% | $-197.1M | $-200.4M | $-0.63 | — |
| Q3 2024 | $1.8M | 95.9% | $-63.7M | $-64.8M | $-0.18 | — |
| Q2 2024 | $1.6M | 89.9% | $-55.4M | $-53.4M | $-0.17 | — |
| Q1 2024 | $1.1M | 84.5% | $-45.3M | $-48.4M | $-0.20 | — |
| Q4 2023 | $702.0K | -2012.8% | $-46.7M | $-49.8M | $-0.20 | — |
| FY 2023 | $1.2M | -4798.0% | $-171.8M | $-177.1M | $-0.80 | — |